Weekly Research Analysts’ Ratings Changes for Virax Biolabs Group (VRAX)

Virax Biolabs Group (NASDAQ: VRAX) has recently received a number of price target changes and ratings updates:

• 7/13/2026 – Virax Biolabs Group was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/6/2026 – Virax Biolabs Group had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/5/2026 – Virax Biolabs Group was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/27/2026 – Virax Biolabs Group was upgraded by Wall Street Zen to “hold”.

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.